메뉴 건너뛰기




Volumn 84, Issue 4, 2010, Pages 337-344

Synergistic action of the novel HSP90 inhibitor NVP-AUY922 with histone deacetylase inhibitors, melphalan, or doxorubicin in multiple myeloma

Author keywords

Doxorubicin; Heat shock protein; Histone deacetylase; Melphalan; Multiple myeloma

Indexed keywords

5 (2,4 DIHYDROXY 5 ISOPROPYLPHENYL) 4 (4 MORPHOLINOMETHYLPHENYL) 3 ISOXAZOLECARBOXYLIC ACID ETHYLAMIDE; DOXORUBICIN; HEAT SHOCK PROTEIN 90 INHIBITOR; HISTONE DEACETYLASE INHIBITOR; MELPHALAN; PANOBINOSTAT; VORINOSTAT;

EID: 77949443606     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2009.01403.x     Document Type: Article
Times cited : (38)

References (32)
  • 1
    • 42449114035 scopus 로고    scopus 로고
    • Multiple myeloma
    • Kyle RA, Rajkumar SV. Multiple myeloma. Blood 2008;111: 2962-72.
    • (2008) Blood , vol.111 , pp. 2962-2972
    • Kyle, R.A.1    Rajkumar, S.V.2
  • 2
    • 63849093676 scopus 로고    scopus 로고
    • Myeloma bone disease: Recent advances in biology, diagnosis and treatment
    • Sezer O. Myeloma bone disease: recent advances in biology, diagnosis and treatment. Oncologist 2009;14:276-83.
    • (2009) Oncologist , vol.14 , pp. 276-283
    • Sezer, O.1
  • 3
    • 51649090583 scopus 로고    scopus 로고
    • Incorporation of the bone marker carboxy-terminal telopeptide of type-1 collagen improves prognostic information of the International Staging System in newly diagnosed symptomatic multiple myeloma
    • Jakob C, Sterz J, Liebisch P, et al. Incorporation of the bone marker carboxy-terminal telopeptide of type-1 collagen improves prognostic information of the International Staging System in newly diagnosed symptomatic multiple myeloma. Leukemia 2008;22:1767-72.
    • (2008) Leukemia , vol.22 , pp. 1767-1772
    • Jakob, C.1    Sterz, J.2    Liebisch, P.3
  • 4
    • 34548133601 scopus 로고    scopus 로고
    • Bortezomib inhibits human osteoclastogenesis
    • von Metzler I, Krebbel H, Hecht M, et al. Bortezomib inhibits human osteoclastogenesis. Leukemia 2007;21: 2025-34.
    • (2007) Leukemia , vol.21 , pp. 2025-2034
    • von Metzler, I.1    Krebbel, H.2    Hecht, M.3
  • 5
    • 34548128339 scopus 로고    scopus 로고
    • The effect of novel anti-myeloma agents on bone metabolism of patients with multiple myeloma
    • Terpos E, Dimopoulos MA, Sezer O. The effect of novel anti-myeloma agents on bone metabolism of patients with multiple myeloma. Leukemia 2007;21:1875-84.
    • (2007) Leukemia , vol.21 , pp. 1875-1884
    • Terpos, E.1    Dimopoulos, M.A.2    Sezer, O.3
  • 6
    • 34447335316 scopus 로고    scopus 로고
    • Osteoblasts promote migration and invasion of myeloma cells through upregulation of matrix metalloproteinases, urokinase plasminogen activator, hepatocyte growth factor and activation of p38 MAPK
    • Hecht M, Heider U, Kaiser M, von Metzler I, Sterz J, Sezer O. Osteoblasts promote migration and invasion of myeloma cells through upregulation of matrix metalloproteinases, urokinase plasminogen activator, hepatocyte growth factor and activation of p38 MAPK. Br J Haematol 2007;138:446-58.
    • (2007) Br J Haematol , vol.138 , pp. 446-458
    • Hecht, M.1    Heider, U.2    Kaiser, M.3    von Metzler, I.4    Sterz, J.5    Sezer, O.6
  • 7
    • 34447266200 scopus 로고    scopus 로고
    • An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-MY20) in assessing the quality of life of patients with multiple myeloma
    • Cocks K, Cohen D, Wisloff F, et al. An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-MY20) in assessing the quality of life of patients with multiple myeloma. Eur J Cancer 2007;43:1670-8.
    • (2007) Eur J Cancer , vol.43 , pp. 1670-1678
    • Cocks, K.1    Cohen, D.2    Wisloff, F.3
  • 8
    • 54049135250 scopus 로고    scopus 로고
    • Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: Updated results of a randomized controlled trial
    • Palumbo A, Bringhen S, Liberati AM, et al. Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial. Blood 2008;112:3107-14.
    • (2008) Blood , vol.112 , pp. 3107-3114
    • Palumbo, A.1    Bringhen, S.2    Liberati, A.M.3
  • 9
    • 50449086728 scopus 로고    scopus 로고
    • Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma
    • San Miguel JF, Schlag R, Khuageva NK, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008;359:906-17.
    • (2008) N Engl J Med , vol.359 , pp. 906-917
    • San Miguel, J.F.1    Schlag, R.2    Khuageva, N.K.3
  • 11
    • 25844519550 scopus 로고    scopus 로고
    • HSP90 and the chaperoning of cancer
    • Whitesell L, Lindquist SL. HSP90 and the chaperoning of cancer. Nat Rev Cancer 2005;5:761-72.
    • (2005) Nat Rev Cancer , vol.5 , pp. 761-772
    • Whitesell, L.1    Lindquist, S.L.2
  • 13
    • 33644554220 scopus 로고    scopus 로고
    • The effects of the histone deacetylase inhibitor valproic acid on cell cycle, growth suppression and apoptosis in multiple myeloma
    • Kaiser M, Zavrski I, Sterz J, Jakob C, Fleissner C, Kloetzel PM, Sezer O, Heider U. The effects of the histone deacetylase inhibitor valproic acid on cell cycle, growth suppression and apoptosis in multiple myeloma. Haematologica 2006;91:248-51.
    • (2006) Haematologica , vol.91 , pp. 248-251
    • Kaiser, M.1    Zavrski, I.2    Sterz, J.3    Jakob, C.4    Fleissner, C.5    Kloetzel, P.M.6    Sezer, O.7    Heider, U.8
  • 14
    • 31544436323 scopus 로고    scopus 로고
    • Antimyeloma activity of heat shock protein-90 inhibition
    • Mitsiades CS, Mitsiades NS, McMullan CJ, et al. Antimyeloma activity of heat shock protein-90 inhibition. Blood 2006;107:1092- 100.
    • (2006) Blood , vol.107 , pp. 1092-1100
    • Mitsiades, C.S.1    Mitsiades, N.S.2    McMullan, C.J.3
  • 15
    • 49449105426 scopus 로고    scopus 로고
    • Signalling profile and antitumour activity of the novel Hsp90 inhibitor NVP-AUY922 in multiple myeloma
    • Stuhmer T, Zollinger A, Siegmund D, et al. Signalling profile and antitumour activity of the novel Hsp90 inhibitor NVP-AUY922 in multiple myeloma. Leukemia 2008;22:1604-12.
    • (2008) Leukemia , vol.22 , pp. 1604-1612
    • Stuhmer, T.1    Zollinger, A.2    Siegmund, D.3
  • 16
    • 28644440158 scopus 로고    scopus 로고
    • Histone deacetylase inhibitors: Discovery and development as anticancer agents
    • Marks PA, Dokmanovic M. Histone deacetylase inhibitors: discovery and development as anticancer agents. Expert Opin Investig Drugs 2005;14:1497-511.
    • (2005) Expert Opin Investig Drugs , vol.14 , pp. 1497-1511
    • Marks, P.A.1    Dokmanovic, M.2
  • 17
    • 22844432021 scopus 로고    scopus 로고
    • Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: A novel basis for antileukemia activity of histone deacetylase inhibitors
    • Bali P, Pranpat M, Bradner J, et al. Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors. J Biol Chem 2005;280:26729-34.
    • (2005) J Biol Chem , vol.280 , pp. 26729-26734
    • Bali, P.1    Pranpat, M.2    Bradner, J.3
  • 19
    • 0021118703 scopus 로고
    • Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors
    • Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984;22:27-55.
    • (1984) Adv Enzyme Regul , vol.22 , pp. 27-55
    • Chou, T.C.1    Talalay, P.2
  • 20
    • 0043164960 scopus 로고    scopus 로고
    • Proteasome inhibitors induce growth inhibition and apoptosis in myeloma cell lines and in human bone marrow myeloma cells irrespective of chromosome 13 deletion
    • Zavrski I, Naujokat C, Niemoller K, et al. Proteasome inhibitors induce growth inhibition and apoptosis in myeloma cell lines and in human bone marrow myeloma cells irrespective of chromosome 13 deletion. J Cancer Res Clin Oncol 2003;129:383-91.
    • (2003) J Cancer Res Clin Oncol , vol.129 , pp. 383-391
    • Zavrski, I.1    Naujokat, C.2    Niemoller, K.3
  • 21
    • 65349193958 scopus 로고    scopus 로고
    • Bortezomib, ascorbic acid and melphalan (BAM) therapy for patients with newly diagnosed multiple myeloma: An effective and well-tolerated frontline regimen
    • Berenson JR, Yellin O, Woytowitz D, et al. Bortezomib, ascorbic acid and melphalan (BAM) therapy for patients with newly diagnosed multiple myeloma: an effective and well-tolerated frontline regimen. Eur J Haematol 2009; 82:433-9.
    • (2009) Eur J Haematol , vol.82 , pp. 433-439
    • Berenson, J.R.1    Yellin, O.2    Woytowitz, D.3
  • 22
    • 33644843725 scopus 로고    scopus 로고
    • Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: Randomised controlled trial
    • Palumbo A, Bringhen S, Caravita T, et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet 2006;367:825-31.
    • (2006) Lancet , vol.367 , pp. 825-831
    • Palumbo, A.1    Bringhen, S.2    Caravita, T.3
  • 23
    • 33947386313 scopus 로고    scopus 로고
    • Synergism between etoposide and 17-AAG in leukemia cells: Critical roles for Hsp90, FLT3, topoisomerase II, Chk1, and Rad51
    • Yao Q, Weigel B, Kersey J. Synergism between etoposide and 17-AAG in leukemia cells: critical roles for Hsp90, FLT3, topoisomerase II, Chk1, and Rad51. Clin Cancer Res 2007;13:1591-600.
    • (2007) Clin Cancer Res , vol.13 , pp. 1591-1600
    • Yao, Q.1    Weigel, B.2    Kersey, J.3
  • 24
    • 0038404927 scopus 로고    scopus 로고
    • Inhibition of heat shock protein 90 function down-regulates Akt kinase and sensitizes tumors to Taxol
    • Solit DB, Basso AD, Olshen AB, Scher HI, Rosen N. Inhibition of heat shock protein 90 function down-regulates Akt kinase and sensitizes tumors to Taxol. Cancer Res 2003;63:2139-44.
    • (2003) Cancer Res , vol.63 , pp. 2139-2144
    • Solit, D.B.1    Basso, A.D.2    Olshen, A.B.3    Scher, H.I.4    Rosen, N.5
  • 25
    • 22044437522 scopus 로고    scopus 로고
    • Heat shock protein 90 inhibition sensitizes acute myelogenous leukemia cells to cytarabine
    • Mesa RA, Loegering D, Powell HL, et al. Heat shock protein 90 inhibition sensitizes acute myelogenous leukemia cells to cytarabine. Blood 2005;106:318-27.
    • (2005) Blood , vol.106 , pp. 318-327
    • Mesa, R.A.1    Loegering, D.2    Powell, H.L.3
  • 26
    • 21744462772 scopus 로고    scopus 로고
    • Synergistic activity of imatinib and 17-AAG in imatinib-resistant CML cells overexpressing BCR-ABL-Inhibition of P-glycoprotein function by 17-AAG
    • Radujkovic A, Schad M, Topaly J, et al. Synergistic activity of imatinib and 17-AAG in imatinib-resistant CML cells overexpressing BCR-ABL-Inhibition of P-glycoprotein function by 17-AAG. Leukemia 2005;19:1198-206.
    • (2005) Leukemia , vol.19 , pp. 1198-1206
    • Radujkovic, A.1    Schad, M.2    Topaly, J.3
  • 28
    • 20844444898 scopus 로고    scopus 로고
    • Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3
    • George P, Bali P, Annavarapu S, et al. Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3. Blood 2005;105:1768-76.
    • (2005) Blood , vol.105 , pp. 1768-1776
    • George, P.1    Bali, P.2    Annavarapu, S.3
  • 29
    • 52649133274 scopus 로고    scopus 로고
    • HDAC6 inhibition enhances 17-AAG-mediated abrogation of hsp90 chaperone function in human leukemia cells
    • Rao R, Fiskus W, Yang Y, et al. HDAC6 inhibition enhances 17-AAG-mediated abrogation of hsp90 chaperone function in human leukemia cells. Blood 2008;112:1886-93.
    • (2008) Blood , vol.112 , pp. 1886-1893
    • Rao, R.1    Fiskus, W.2    Yang, Y.3
  • 30
    • 0034890377 scopus 로고    scopus 로고
    • Modulation of Hsp90 function by ansamycins sensitizes breast cancer cells to chemotherapy-induced apoptosis in an RB- and schedule-dependent manner
    • Munster PN, Basso A, Solit D, Norton L, Rosen N. Modulation of Hsp90 function by ansamycins sensitizes breast cancer cells to chemotherapy-induced apoptosis in an RB- and schedule-dependent manner. Clin Cancer Res 2001;7:2228-36.
    • (2001) Clin Cancer Res , vol.7 , pp. 2228-2236
    • Munster, P.N.1    Basso, A.2    Solit, D.3    Norton, L.4    Rosen, N.5
  • 31
    • 0034886833 scopus 로고    scopus 로고
    • Combining cytotoxics and 17-allylamino, 17-demethoxygeldanamycin: Sequence and tumor biology matters
    • Sausville EA. Combining cytotoxics and 17-allylamino, 17-demethoxygeldanamycin: sequence and tumor biology matters. Clin Cancer Res 2001;7:2155-8.
    • (2001) Clin Cancer Res , vol.7 , pp. 2155-2158
    • Sausville, E.A.1
  • 32
    • 33751203833 scopus 로고    scopus 로고
    • Heat shock proteins 27 and 70: Anti-apoptotic proteins with tumorigenic properties
    • Garrido C, Brunet M, Didelot C, Zermati Y, Schmitt E, Kroemer G. Heat shock proteins 27 and 70: anti-apoptotic proteins with tumorigenic properties. Cell Cycle 2006;5:2592-601.
    • (2006) Cell Cycle , vol.5 , pp. 2592-2601
    • Garrido, C.1    Brunet, M.2    Didelot, C.3    Zermati, Y.4    Schmitt, E.5    Kroemer, G.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.